Application of FDG Combined With FAPI PET Dual Imaging in the Diagnosis and Staging of Oropharyngeal and Laryngeal Cancer

Diagnostic efficacy

According to statistics, in 2020, new head and neck malignancies in the world accounted for
 4.9% (931931 cases) of malignant tumors in the whole body, and the new death cases were
 467125, accounting for 4.7% of malignant tumors in the whole body. The high incidence rate
 and mortality brought great burden to the medical system. In addition, due to various types
 of head and neck cancer, hidden location, impact on function and quality of life, and low
 overall survival rate, this type of disease has seriously threatened human health and social
 development. The incidence of oropharyngeal cancer and laryngeal cancer is more subtle.
 Traditional examination methods include CT(computer tomography), MR(magnetic resonance), and
 laryngoscopy, but they cannot make accurate judgments on the systemic TNM(primary tumor,
 regional nodes, metastasis) staging of oropharyngeal cancer and laryngeal cancer.
 18F-FDG(18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose) PET/CT examination can better
 diagnose and stage compared to traditional examination methods. However, due to the
 interference of more inflammatory lesions or physiological uptake in the pharynx, the false
 positive rate of 18F-FDG PET/CT examination is significantly increased,
 18F-FAPI(18F-fibroblast activation protein inhibitors) is a novel broad-spectrum tumor
 imaging agent that can be specifically uptake by fibroblasts in the tumor microenvironment,
 and has lower physiological uptake and acute inflammatory lesion uptake in the larynx.
 18F-FAPI PET/CT examination can more accurately stage tumors throughout the body than 18F-FDG
 PET/CT examination. Combined with PET/MR local scanning, it will further improve the accuracy
 of T and N staging of local tumors. Therefore, It is of great significance for clinical
 diagnosis and treatment to effectively and reliably determine the systemic TNM staging of
 oropharyngeal and laryngeal cancer through non-invasive methods.